UK trial launches to transform Alzheimer’s diagnosis with simple blood test
On Sept. 10, 2025, a major University of London (UCL)-led clinical trial, aiming to transform the diagnosis of…
Complete brain activity map revealed for the first time
On Sept. 3, 2025, The International Brain Laboratory (IBL) researchers published their findings today in two papers in Nature, revealing…
C2N Diagnostics Expands St. Louis Headquarters to Meet Global Need for Answers to Alzheimer’s Disease
On Sept. 3, 2025, C2N Diagnostics (C2N), a specialty diagnostics company announce that its early achievements while based…
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
On Sept. 2, 2025, Arrowhead Pharmaceuticals announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s…
Biotechnology | Diagnostics | Disease | Neurology | Oncology
New genetic biomarker flags aggressive brain tumors
On Sept. 1, 2025, a multi-institutional study suggests that typically classifiication of meningiomas by appearances may be deceiving…
Artificial Intelligence | Biotechnology | Genomics | Nanotechnology | Neurology | Non-Profit Research
Microsoft co-founder Paul Allen’s final act: New $3.1B foundation bets big on science and tech
On Aug. 27, 2025, a new fun created by Allen’s estate under the late Microsoft co-founder’s instructions, was…
AbbVie to Acquire Gilgamesh Pharma’s Investigational Therapy for Major Depressive Disorder for $1.2 Billion
On Aug. 25, 2025, AbbVie and Gilgamesh Pharmaceuticals announced a definitive agreement under which AbbVie will acquire Gilgamesh’s…
C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older
On Aug. 25, 2025, C2N Diagnostics (C2N) announced lower age limit addresses increasing calls from clinicians seeking access…
Skyhawk Therapeutics Announces Strategic Collaboration with Merck to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders
On Aug. 18, 2025, Skyhawk Therapeutics announces a strategic research collaboration with Merck KGaA, Darmstadt, Germany. The collaboration…
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
On Aug. 6, 2025, Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso™ (dordaviprone)…
MIT spinout Tissium secured FDA marketing authorization of biopolymer platform for nerve repair
On Aug. 1, 2025, Tissium announced it has begun offering surgeons a new solution based on a biopolymer…
Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park
On Jul. 31, 2025, Biogen announced it intends to invest an additional $2 billion in its existing manufacturing footprint…
Nature-Inspired Virtual Reality Boosts Emotional Well-Being In Older Adults Living With Dementia
On Jul. 29, 2025, Texas A&M study finds immersive VR nature experiences improve mood and quality of life….
Neural anticipation of virtual infection triggers an immune response
On Jul. 28, 2025, a study published in Nature Neuroscience shows that potential contact with approaching infectious avatars,…
Remote programs effective for chronic pain, study finds
On Jul. 28, 2025, Kaiser Permanente Washington Health Research Institute (KPWHRI) and Kaiser Permanente Center for Health Research…
Long-term exposure to outdoor air pollution linked to increased risk of dementia
On Jul. 24, 2025, an analysis of studies incorporating data from almost 30 million people has highlighted the…
Biology | Disease | Neurology | Therapeutics
How B Vitamins Can Affect Brain and Heart Health
On Jul. 23, 2025, research at Tufts and elsewhere has revealed the eight essential nutrients that make up…
Diagnostics | Disease | Energy | Environmental | EPA | Neurology | U.S. Congress
EPA eliminates research and development office, begins layoffs
On Jul. 18, 2025, The Environmental Protection Agency (EPA) said it is eliminating its research and development arm…
C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer’s Disease and Related Dementias
On Jul. 15, 2025, C2N Diagnostics (C2N), announces the launch of two new highly anticipated plasma assays for…
Northwestern scientists studied 174 brain samples. CTE and aging were difficult to distinguish
On Jul. 11, 2025, findings from Northwestern University study show the brain protein tied to CTE is not…
Biotechnology | Disease | FDA | Neurology | Therapeutics
FDA approves updated label for Lilly’s Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer’s disease
On Jul. 9, 2025, Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has approved a…
New research confirms that neurons form in the adult brain
On Jul. 3, 2025, a study in the journal Science presents compelling new evidence that neurons in the…
Parkinson’s drug effective in treating persistent depression
On Jun. 30, 2025, a University of Oxford led study reported that a drug used for Parkinson’s disease…
Supernus Pharmaceuticals to Acquire Sage Therapeutics
On Jun. 16, 2025, Supernus Pharmaceuticals and Sage Therapeutics announced a definitive agreement for Supernus to acquire Sage…
Scientists can now target the cells at the center of ALS
On Jun. 16, 2025, the Allen Institute announced that for the first time ever, scientists have developed a…
BrainStorm Announces New Survival Data from Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn
On Jun. 16, 2025, BrainStorm Cell Therapeutics announced new survival data from 10 participants in its Expanded Access…
Scientists map the first step in Alzheimer’s protein aggregation and discover clues for future therapies
On Jun. 11, 2025, researchers from the Wellcome Sanger Institute, Centre of Genomic Regulation (CRG) and Institute for…
First-of-its-kind technology helps man with ALS ‘speak’ in real time
On Jun. 11, 2025, researchers at the University of California, Davis, announced they have developed an investigational brain-computer…
LinusBio Launches Groundbreaking ClearStrand-ASD to aid Health Care Providers in Ruling Out Autism Using a Single Strand of Hair
On Jun. 5, 2025, LinusBio announced ClearStrand-ASD™, a first-of-its-kind diagnostic aid for autism spectrum disorder (ASD). ClearStrand-ASD is…
Common gene variant doubles dementia risk for men
On May 30, 2025, researchers from Curtin Medical School reported that they have found that men who carry…